ATARA Biotherapeutics (ATRA) Misses Q4 EPS by 27c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. NVDA
2. PCVX
3. PTC
4. META
5. MSFT
6. SPY
7. GMAB
8. USO
9. GOOGL
10. AMD

Go back to ATARA Biotherapeutics (ATRA) Misses Q4 EPS by 27c

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress

February 28, 2022 4:05 PM EST

Tab-cel U.S. BLA Submission Not Currently Expected for Q2 2022 as Further FDA Engagement and Alignment Required; Anticipated EU Approval On-Track for Q4 2022 Under Accelerated Assessment

ATA188 Granted FDA Fast Track Designation in Both Non-Active PPMS and Non-Active SPMS with Phase 2 EMBOLD Study Interim Analysis Planned for Q2 2022

Entered Long-Term Strategic Manufacturing Partnership with Fujifilm with Upfront Cash Payment of USD 100 Million

Conference Call and Webcast Today at 1:30 p.m. PST/ 4:30 p.m. EST

SOUTH SAN FRANCISCO, Calif.--(BUSINESS... More